{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:43:08Z","timestamp":1790908988034,"version":"4.1.0"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100012479","name":"Weston Brain Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009307","name":"Parkinson Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009307","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.neuropharm.2020.108386","type":"journal-article","created":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T19:57:11Z","timestamp":1604347031000},"page":"108386","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Selective blockade of the 5-HT3 receptor acutely alleviates dyskinesia and psychosis in the parkinsonian marmoset"],"prefix":"10.1016","volume":"182","author":[{"given":"Cynthia","family":"Kwan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen G.","family":"Nuara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"B\u00e9dard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fleur","family":"Gaudette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim C.","family":"Gourdon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Beaudry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Huot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2020.108386_bib1","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ibror.2018.12.001","article-title":"Anti-dyskinetic efficacy of 5-HT3 receptor antagonist in the hemi-parkinsonian rat model","volume":"6","author":"Aboulghasemi","year":"2018","journal-title":"IBRO reports"},{"key":"10.1016\/j.neuropharm.2020.108386_bib2","first-page":"11","article-title":"Clinical pharmacology of ondansetron in postoperative nausea and vomiting","volume":"6","author":"Baber","year":"1992","journal-title":"Eur. J. Anaesthesiol. Suppl."},{"key":"10.1016\/j.neuropharm.2020.108386_bib3","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/0014-2999(93)90282-M","article-title":"SR 57227A: a potent and selective agonist at central and peripheral 5-HT3 receptors in vitro and in vivo","volume":"237","author":"Bachy","year":"1993","journal-title":"Eur. J. Pharmacol."},{"issue":"10","key":"10.1016\/j.neuropharm.2020.108386_bib4","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s00702-020-02247-2","article-title":"The MPTP-lesioned marmoset model of Parkinson\u2019s disease: proposed efficacy thresholds that may potentially predict successful clinical trial results","volume":"127","author":"Beaudry","year":"2020","journal-title":"J. Neural. Transm. (Vienna)"},{"key":"10.1016\/j.neuropharm.2020.108386_bib5","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0022-3565(25)38133-4","article-title":"Serotonin-facilitated dopamine release in vivo: pharmacological characterization","volume":"265","author":"Benloucif","year":"1993","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2020.108386_bib6","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/mds.25366","article-title":"Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia","volume":"28","author":"Bezard","year":"2013","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2020.108386_bib7","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0022-3565(25)21081-3","article-title":"Release of endogenous dopamine by stimulation of 5-hydroxytryptamine3 receptors in rat striatum","volume":"251","author":"Blandina","year":"1989","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2020.108386_bib8","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1124\/jpet.118.247650","article-title":"Pharmacokinetic\/Pharmacodynamic correlation analysis of amantadine for levodopa-induced dyskinesia","volume":"367","author":"Brigham","year":"2018","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2020.108386_bib9","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/0006-3223(94)00378-5","article-title":"L-DOPA and psychosis: evidence for L-DOPA-induced increases in prefrontal cortex dopamine and in serum corticosterone","volume":"38","author":"Carey","year":"1995","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2020.108386_bib10","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/brain\/awm082","article-title":"Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats","volume":"130","author":"Carta","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2020.108386_bib11","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s40265-016-0600-5","article-title":"Psychosis in Parkinson's disease: epidemiology, pathophysiology, and management","volume":"76","author":"Chang","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.neuropharm.2020.108386_bib12","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/jps.2600800913","article-title":"Determination of ondansetron in plasma and its pharmacokinetics in the young and elderly","volume":"80","author":"Colthup","year":"1991","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2020.108386_bib13","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1111\/j.1476-5381.1987.tb11394.x","article-title":"Effects of the 5-HT3 receptor antagonist, GR38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain","volume":"92","author":"Costall","year":"1987","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108386_bib14","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","article-title":"Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial","volume":"383","author":"Cummings","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2020.108386_bib15","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1093\/brain\/awh102","article-title":"Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model","volume":"127","author":"de la Fuente-Fernandez","year":"2004","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2020.108386_bib16","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/nrneurol.2009.62","article-title":"Hallucinations in Parkinson disease","volume":"5","author":"Diederich","year":"2009","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.neuropharm.2020.108386_bib17","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S1474-4422(18)30295-3","article-title":"Global, regional, and national burden of Parkinson's disease, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"17","author":"Dorsey","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2020.108386_bib18","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1080\/01621459.1980.10477552","article-title":"Pairwise multiple comparisons in the unequal variance case","volume":"75","author":"Dunnett","year":"1980","journal-title":"J. Am. Stat. Assoc."},{"key":"10.1016\/j.neuropharm.2020.108386_bib19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1471-2377-9-23","article-title":"Dopamine Agonists and their risk to induce psychotic episodes in Parkinson's disease: a case-control study","volume":"9","author":"Ecker","year":"2009","journal-title":"BMC Neurol."},{"key":"10.1016\/j.neuropharm.2020.108386_bib20","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1212\/WNL.47.6.1608-b","article-title":"Ondansetron treatment of L-dopa-induced psychosis","volume":"47","author":"Eichhorn","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2020.108386_bib21","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S1474-4422(17)30299-5","article-title":"Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"16","author":"Feigin","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2020.108386_bib22","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/mds.27372","article-title":"International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson's disease","volume":"33","author":"Fox","year":"2018","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2020.108386_bib23","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1017\/S0317167100009707","article-title":"Neuropsychiatric behaviors in the MPTP marmoset model of Parkinson's disease","volume":"37","author":"Fox","year":"2010","journal-title":"Can. J. Neurol. Sci."},{"key":"10.1016\/j.neuropharm.2020.108386_bib24","first-page":"280","article-title":"Parkinson Psychosis Rating Scale: a practical instrument for grading psychosis in Parkinson's disease","volume":"21","author":"Friedberg","year":"1998","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.neuropharm.2020.108386_bib25","doi-asserted-by":"crossref","first-page":"112766","DOI":"10.1016\/j.jpba.2019.07.014","article-title":"Highly sensitive HPLC-MS\/MS assay for the quantitation of ondansetron in rat plasma and rat brain tissue homogenate following administration of a very low subcutaneous dose","volume":"175","author":"Gaudette","year":"2019","journal-title":"J. Pharmaceut. Biomed. Anal."},{"key":"10.1016\/j.neuropharm.2020.108386_bib26","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jchromb.2017.07.007","article-title":"Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method to quantify LY\u2010354,740 in rat and marmoset plasma","volume":"1061\u20131062","author":"Gaudette","year":"2017","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.neuropharm.2020.108386_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchromb.2018.06.036","article-title":"Development of a selective and sensitive high-performance liquid chromatography-tandem mass spectrometry assay to support pharmacokinetic studies of LY-487,379 in rat and marmoset","volume":"1093\u20131094","author":"Gaudette","year":"2018","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.neuropharm.2020.108386_bib28","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/BF02289823","article-title":"On methods in the analysis of profile data","volume":"24","author":"Greenhouse","year":"1959","journal-title":"Psychometrika"},{"key":"10.1016\/j.neuropharm.2020.108386_bib29","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.parkreldis.2013.01.009","article-title":"Safinamide reduces dyskinesias and prolongs L-DOPA antiparkinsonian effect in parkinsonian monkeys","volume":"19","author":"Gr\u00e9goire","year":"2013","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.neuropharm.2020.108386_bib30","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/0014-2999(87)90450-X","article-title":"Effect of the 5-HT3 receptor antagonist, GR38032F, on responses to injection of a neurokinin agonist into the ventral tegmental area of the rat brain","volume":"138","author":"Hagan","year":"1987","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108386_bib31","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1476-5381.1990.tb14685.x","article-title":"Effect of 5-HT3 receptor antagonists on responses to selective activation of mesolimbic dopaminergic pathways in the rat","volume":"99","author":"Hagan","year":"1990","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108386_bib32","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.neuropharm.2018.06.038","article-title":"The highly selective 5-HT2A antagonist EMD-281,014 reduces dyskinesia and psychosis in the L-DOPA-treated parkinsonian marmoset","volume":"139","author":"Hamadjida","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2020.108386_bib33","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s00213-017-4530-z","article-title":"The effect of mirtazapine on dopaminergic psychosis and dyskinesia in the parkinsonian marmoset","volume":"234","author":"Hamadjida","year":"2017","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2020.108386_bib35","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/mds.20324","article-title":"Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years","volume":"20","author":"Hely","year":"2005","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2020.108386_bib36","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/mds.21956","article-title":"The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years","volume":"23","author":"Hely","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2020.108386_bib37","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1124\/jpet.104.066191","article-title":"Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease","volume":"310","author":"Hill","year":"2004","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2020.108386_bib38","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/mds.23083","article-title":"Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations","volume":"25","author":"Huot","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2020.108386_bib39","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1124\/jpet.106.110429","article-title":"In 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with increased motor disability","volume":"319","author":"Iravani","year":"2006","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2020.108386_bib40","first-page":"647","article-title":"[The effects of ondansetron, a 5-HT3 receptor antagonist, on medication-induced hallucinations in Parkinson's disease]","volume":"16","author":"Kazunori","year":"1999","journal-title":"Neurol Ther"},{"key":"10.1016\/j.neuropharm.2020.108386_bib41","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0166-4328(96)00063-0","article-title":"5-HT3 and 5-HT4 receptors in terminal regions of the mesolimbic system","volume":"73","author":"Kilpatrick","year":"1996","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2020.108386_bib42","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/mds.25859","article-title":"Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease","volume":"29","author":"Ko","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2020.108386_bib43","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1002\/mds.23867","article-title":"Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease","volume":"26","author":"Kobylecki","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2020.108386_bib44","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1139\/cjpp-2019-0551","article-title":"Pharmacokinetic profile of the selective 5-HT(3) receptor antagonist ondansetron in the rat: an original study and a minireview of the behavioural pharmacological literature in the rat","volume":"98","author":"Kwan","year":"2020","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108386_bib45","article-title":"Granisetron, a selective 5-HT3 antagonist, reduces L-DOPA-induced abnormal involuntary movements in the 6-OHDA-lesioned rat","author":"Kwan","year":"2020","journal-title":"Behav Pharmacol"},{"key":"10.1016\/j.neuropharm.2020.108386_bib46","doi-asserted-by":"crossref","first-page":"172914","DOI":"10.1016\/j.ejphar.2020.172914","article-title":"Ondansetron, a highly selective 5-HT(3) receptor antagonist, reduces L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease","volume":"871","author":"Kwan","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108386_bib47","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00221-018-5434-9","article-title":"5-HT2A blockade for dyskinesia and psychosis in Parkinson's disease: is there a limit to the efficacy of this approach? A study in the MPTP-lesioned marmoset and a literature mini-review","volume":"237","author":"Kwan","year":"2019","journal-title":"Exp. Brain Res."},{"key":"10.1016\/j.neuropharm.2020.108386_bib48","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2217\/nmt-2019-0014","article-title":"5-HT(3) receptors in Parkinson's disease psychosis: a forgotten target?","volume":"9","author":"Kwan","year":"2019","journal-title":"Neurodegener. Dis. Manag."},{"key":"10.1016\/j.neuropharm.2020.108386_bib49","first-page":"S14","article-title":"Psychosis: impact on the patient and family","volume":"52","author":"Melamed","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2020.108386_bib50","series-title":"Zofran ODT (Ondansetron) [package Insert on the Internet]","year":"1999"},{"key":"10.1016\/j.neuropharm.2020.108386_bib51","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/mds.26159","article-title":"Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study)","volume":"30","author":"Pahwa","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2020.108386_bib52","series-title":"Clinical Pharmacokinetics: Concepts and Application","author":"Rowland","year":"1995"},{"key":"10.1016\/j.neuropharm.2020.108386_bib53","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1111\/j.1476-5381.1995.tb16371.x","article-title":"5-HT3 receptor agonist induced carrier-mediated release of dopamine in rat striatum in vivo","volume":"116","author":"Santiago","year":"1995","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108386_bib54","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/mds.27602","article-title":"Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review","volume":"34","author":"Seppi","year":"2019","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2020.108386_bib55","first-page":"355","article-title":"Effect of the 5-HT3 receptor antagonist ondansetron on amphetamine-induced hyperactivity and stereotypy in rats","volume":"44","author":"Shankar","year":"2000","journal-title":"Indian J. Physiol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108386_bib68","doi-asserted-by":"crossref","first-page":"172957","DOI":"10.1016\/j.ejphar.2020.172957","article-title":"Selective metabotropic glutamate receptor 2 positive allosteric modulation alleviates L-DOPA-induced psychosis-like behaviours and dyskinesia in the MPTP-lesioned marmoset","volume":"28873","author":"Sid-Otmane","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108386_bib56","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S1474-4422(18)30209-6","article-title":"Difficult choices in treating Parkinson\u2019s disease psychosis","volume":"17","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2020.108386_bib57","first-page":"141","article-title":"Duration of amantadine benefit on dyskinesia of severe Parkinson's disease","volume":"75","author":"Thomas","year":"2004","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.neuropharm.2020.108386_bib58","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/0922-4106(90)90190-9","article-title":"The concept of selectivity in 5-HT receptor research","volume":"188","author":"van Wijngaarden","year":"1990","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108386_bib59","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1093\/ajhp\/57.11.1046","article-title":"Pharmacokinetics of three formulations of ondansetron hydrochloride in healthy volunteers: 24-mg oral tablet, rectal suppository, and i.v. infusion","volume":"57","author":"VanDenBerg","year":"2000","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.neuropharm.2020.108386_bib60","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1124\/jpet.117.247171","article-title":"Predictive value of parkinsonian primates in pharmacologic studies: a comparison between the macaque, marmoset, and squirrel monkey","volume":"365","author":"Veyres","year":"2018","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2020.108386_bib61","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/0306-4522(89)90382-5","article-title":"5-Hydroxytryptamine3 receptors in the human brain: autoradiographic visualization using [3H]ICS 205-930","volume":"31","author":"Waeber","year":"1989","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2020.108386_bib62","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/s11940-010-0072-y","article-title":"Parkinson's psychosis","volume":"12","author":"Zahodne","year":"2010","journal-title":"Curr. Treat. Options Neurol."},{"key":"10.1016\/j.neuropharm.2020.108386_bib63","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/j.1476-5381.1994.tb17087.x","article-title":"Role of 5-HT3 receptors in basal and K(+)-evoked dopamine release from rat olfactory tubercle and striatal slices","volume":"113","author":"Zazpe","year":"1994","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108386_bib64","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","article-title":"PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel","volume":"99","author":"Zhang","year":"2010","journal-title":"Comput. Methods Progr. Biomed."},{"key":"10.1016\/j.neuropharm.2020.108386_bib65","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/0140-6736(93)90327-D","article-title":"Ondansetron for hallucinosis in advanced Parkinson's disease","volume":"341","author":"Zoldan","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2020.108386_bib66","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1212\/WNL.45.7.1305","article-title":"Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5-HT3 receptor antagonist","volume":"45","author":"Zoldan","year":"1995","journal-title":"Neurology"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390820304548?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390820304548?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:07:11Z","timestamp":1758438431000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390820304548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":66,"alternative-id":["S0028390820304548"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108386","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Selective blockade of the 5-HT3 receptor acutely alleviates dyskinesia and psychosis in the parkinsonian marmoset","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108386","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108386"}}